Cost blocks public access to RSV protection for babies
High costs are preventing newly approved maternal vaccines and antibody treatments for RSV from entering South Africa's public healthcare system, leaving vulnerable infants without protection.
We haven't written up this one. Mail and Guardian has the full story — the link below goes straight to it.